UK markets closed

Autolus Therapeutics plc (AUTL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.49-0.03 (-0.54%)
At close: 4:00PM EDT
5.58 +0.09 (1.64%)
After hours: 04:31PM EDT
Sign in to post a message.
  • C

    90% of the money flow is controlled by the institutions and good small-cap stocks like AUTL are suffering because of the current economic climate. it has nothing to do with AUTL, which has upcoming catalysts and its share price is presently oversold. Small caps tend to suffer in late-stage bull markets because of falling bond prices and rising rates.

    Two points:

    1. According to a recent S.A. story, Avison Capital Partners, AUTL has a market cap of $425mn and a cash reserve of $239mn. Net total operating expenses for the last reported quarter were about $40mn, and at that rate, the company has about 6 quarter’s worth of cash. Of the expenses, R&D costs were approximately $30mn and SG&A was about $9mn.

    The company has moderate funds/institutional ownership, with holdings of roughly 60%. Funds have increased positions this quarter. There’s a moderate 3.83% short interest.

    2. Bottom line - AUTL has been in the market for 3 years, and the stock has consistently fallen. Now that they have data and a major catalyst in about a year, the depressed price makes the stock interesting.

    Separately, I believe macroeconomic trends will reverse in the second half of the year. The supply chain will be restored, the government's free unemployment insurance/PSP payments will end creating a workforce again, then inflation will slow, and SPACs will dry up, which has drained liquidity from the RUT/IWM/and ETF.

    These factors will permit share price recovery in small-caps and biotechs, which are off of their 2021 highs by about 25$.

    Here's a great article for you to read, which should give you optimsim.

    Biotech Bonanza: Promising Second Half Outlook For Biotech Stocks: Sunday, July 25, 2021, 1:23 a.m. ET

    by Tarun Chandra, Prudent Healthcare


    * Biotech stocks had a muted first half with the S&P Biotech Index down year-to-date, and more than 20% lower from its mid-February peak.

    * The decline in biotech stocks coincided with a spike in interest rates and stabilizing interest rates can provide a boost to valuations.

    * M&A has been dormant but conditions exist for a much busier second half.

    * Neurology, particularly treatments for Alzheimer's and Parkinson's diseases, garnered strong investor interest after approval of Biogen's drug, and the upcoming industry conference can be a catalyst for powerful moves.

    Portfolio exposure to biotech stocks can be much more rewarding in the second half.

    Click on this link to read the article:
    Portfolio exposure to biotech stocks can be much more rewarding in the second half.
    Portfolio exposure to biotech stocks can be much more rewarding in the second half.
  • B
    Hey Rev Shark stick this stock up your A Z Z. Along with VERU and the many more that have tanked after your stock of the week recommendation.
  • J
    The company has received innovative licensing and access pathway designation from the UK MHRA for obe-cel, the company's CAR-T cell therapy being investigated in the ongoing trial in R/R aALL).

    ''The ILAP designation, alongside the recent PRIME designation from the EMA, is another step forward in accelerating the review process of this promising therapy,'' said Dr. Christian Itin. ''Obe-cel continues to show the potential to be differentiated on efficacy, durability and safety from other CAR-T cell products and could change standard of care by offering a potentially curative therapy for R/R aALL.''
  • m
    There is a new Seeking Alpha article out this evening that is positive on AUTL.
  • J
    As of the data cut-off date of May 17, twenty patients in Cohort A with R/R aALL had received obe-cel. The therapy was well tolerated, with no patients experiencing Grade 3 or higher CRS. Three patients (15%), all of whom had high leukaemia burden (over 50% blasts), experienced Grade 3 ICANS that resolved swiftly with steroids.

    Of the twenty patients evaluable for efficacy, seventeen achieved minimum residual disease negative complete response at one month. Most notably, the durability of remissions is highly encouraging. Across all treated patients, event free survival at twelve months and twenty-four months is 50.2% with the median not being reached.
  • J
    The second target (along with BCMA) for AUTO8 is CD19. Apart from that, I don't know what other modules they are adding.
  • J
    As of the data cut-off date of May 17, thirteen patients in Cohort D with R/R IBCL had been enrolled in the trial and product was successfully manufactured for twelve patients, with one patient’s cells ongoing in manufacture. As of the data cut-off date, nine had received AUTO1 infusion. Three were pending infusion (including the patient above) and one patient died prior to lymphodepletion due to a Cov infection. Obe-cel was well tolerated and demonstrated a favourable safety profile, despite high disease burden. All treated patients achieved a complete metabolic response and had robust CAR-T engraftment, expansion, and persistence.

    Grade 1 CRS was reported in four patients and Grade 2 CRS in one. No immune effector cell-associated neurotoxicity syndrome of any grade was observed. At a median follow-up of six months (range 4.0-8.1), eight of nine patients were disease free, with one relapse at month six, but was rescued with radiotherapy. One died of a Cov infection at month 5.6 whilst in complete metabolic response.
  • m
    mike s
    I started buying in @ $9 in January and have been buying more on dips. Average price of $6.75. Nice news today... curious how much it runs up... or if this has any staying power.
  • K
    AUTL is the real deal, I can think of another biotech with this strong of data, and cash position compared to MC.
    Undervalued UK company IMO
  • M
    I made a video about Autolus Therapeutics (AUTL stock)
    Check it on YouTube:
    Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom.
    Do not buy Autolus Therapeutics stock before seeing this video!📈 (AUTL Stock Analysis)
  • B
    Too bad there's not options available for this corporation. It would be helpful now.
  • B
    Not sure why I buy biotech. Every time I have lost money. Especially the ones Rev. Shark recommends.
  • B
    Never buy a stock that Rev Shark calls his stock of the week. This is a good example,
  • J
    As of the data cut-off date of Feb 18, ten R/R IBCL patients had received AUTO1 and nine were evaluable. AUTO1 demonstrated a tolerable safety profile in adult patients with R/R low grade B-cell lymphoma despite high disease burden. Early data shows 100% CR rates and excellent engraftment and expansion. Gr1 CRS was reported in four patients and Gr2 CRS in one. No Immune effector cell-associated neurotoxicity syndrome was observed. At a median of 3.1 months (range 1-5.6), 8/9 patients are in ongoing remission. One patient died at month 5.6 due to COV-19.
  • N
    One of the top oncology companies in the world.
  • B
    Neither the analysts nor the public are recognizing the ramifications of recent releases. Highly underrated.
  • D
    Dude no Way!
    100% CR rate with stellar safety in 9 lymphoma patients. $AUTL is very mis-priced
  • M
    I took some money off the table. Will try to get back in when it drops to near 6 tomorrow or I will have missed out on a further run up. Not sure which is right, but I have my money with no risk tonight.
  • T
    Great news, let's go